SML0857

HQL 79

≥98% (HPLC)

• 동의어(들): 4-Benzhydryloxy-1-[3-(1H-tetrazol-5-yl)-propyl]-piperidine
• 실험식(Hill 표기법): C₂₂H₂₇N₅O
• CAS Number: 162641-16-9
• Molecular Weight: 377.48
• UNSPSC 코드: 41106300
• NACRES: NA.77

속성

• Quality Level: 100
• 분석: ≥98% (HPLC)
• 양식: powder
• 색상: white to beige
• solubility: DMSO: 2 mg/mL, clear (warmed)
• 저장 온도: room temp
• SMILES string: [nH]1nnnc1CCCN2CCC(CC2)OC(c4ccccc4)c3ccccc3
• InChI: 1S/C22H27N5O/c1-3-8-18(9-4-1)22(19-10-5-2-6-11-19)28-20-13-16-27(17-14-20)15-7-12-21-23-25-26-24-21/h1-6,8-11,20,22H,7,12-17H2,(H,23,24,25,26)
• InChI key: TZQGXAHOROZEKN-UHFFFAOYSA-N

설명

생화학적/생리학적 작용

HQL 79 is an orally active anti-allergic agent that acts as an antagonist for histamine H1 receptors (H1R), eliciting anti-asthmatic effects. It interacts with prostaglandin (PG) D synthase (H-PGDS) in the catalytic region. It may be potential lead due to its H-PGDS inhibition to treat allergies.

HQL-79 is a selective inhibtor of hematopoietic prostaglandin D (PGD) synthase, one of two synthases involved in the production of Prostaglandin D2 (PGD2) from arachidonic acid. PGD2 is a lipid signaling molecule, which activates two receptors, DP1 involved in centrally mediated processes such as sleep and pain and DP2 involved and inflammation. The two PGD synthases involved in its synthesis are lipocalin-type (L-PGDS) and hematopoietic (H-PDGS), which acts to form PGD2 in mast cells, Th2 cells, microglia, and other inflammatory cells/tissues. HQL-79 selectively inhibited the activity of recombinant H-PGDS with an IC₅₀ of 6 μM and had almost no effect on COX-1, COX-2, m-PGES, or L-PGDS up to 300 μM. HQL-79 has anti-inflammatory activity in vitro and in vivo.

HQL-79 is a selective inhibtor of hematopoietic prostaglandin D (PGD) synthase.

안전성 정보

• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable